Stocktoria
Gain Therapeutics, Inc. GANX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-03-18
Gain Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $55,180 | $140,108 | $164,994 | $28,881 |
| R&D expense | $10.2M | $10.8M | $11.5M | $8.4M | $7.2M | $2.3M |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M | -$3.5M |
| Income tax | $861,118 | $536,815 | $79,275 | $92,976 | $4,008 | $5,386 |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M | -$3.6M |
| EPS (diluted) | $-0.61 | $-0.89 | $-1.71 | $-1.48 | $-1.37 | $-1.33 |
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M | -$3.2M |
| Free cash flow | — | — | — | — | -$12.5M | -$3.3M |
| Cash & equivalents | $20.8M | $10.4M | $11.8M | $7.3M | $36.9M | $7.5M |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M | $9.6M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M | $3.4M |
| Shareholders' equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M | $6.2M |
Growth · year-over-year · Revenue CAGR 24.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | -60.6% | -15.1% | +471.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.